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The concept of “pay for performance” (P4P) applied to the practice of medicine has become a major foundation in current
publicandprivatepayerreimbursementstrategiesforbothinstitutionalandindividualphysicianproviders.“Payforperformance”
programs represent a substantial shift from traditional service-based reimbursement to a system of performance-based provider
payment using ﬁnancial incentives to drive improvements in the quality of care. P4P strategies currently embody rudimentary
structure and process (as opposed to outcomes) metrics which set relatively low-performance thresholds. P4P strategies that align
reimbursement allocation with “free market” type shifts in cognitive and procedural care using evidence-based data and positive
reinforcement are more likely to produce large-scale improvements in quality and cost eﬃciency with respect to clinical urologic
care. This paper reviews current paradigms and, using BPH procedural therapy outcomes, cost, and reimbursement data, makes
the case for a fundamental change in perspective to value-based pay for performance as a reimbursement system with the potential
to align the interests of patients, physicians, and payers and to improve global clinical outcomes while preserving free choice of
clinically eﬃcacious treatments.
Copyright © 2008 M. Stovsky and I. Jaeger. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The concept of “pay for performance” applied to the
practice of medicine has become a major foundation in
current public and private payer reimbursement strategies
for both institutional and individual physician providers.
The number of pay for performance initiatives is growing
nationwide [1]. The goal of these programs is ostensibly
to improve quality of care and to reduce healthcare costs
by linking clinical outcomes metrics with reimbursement
allocationparadigms. Inattempting to achieve this objective,
“pay for performance” programs represent a substantial shift
from traditional service-based reimbursement to a system
of performance-based provider payment using ﬁnancial
incentives to drive improvements in the quality of care.
The current fee for service system is designed to reim-
burse healthcare providers based principally on the volume
of services provided, without consideration for the quality
of clinical outcomes. Clearly, though, the face of health care
resource allocation is changing and payers are beginning
to scrutinize the costs and beneﬁts of various treatment
options. Further, outcomes research and performance-based
reimbursement initiatives are underway which will change
the basis by which the performance of physicians, ancillary
health professionals, and health care institutions are assessed
by payers [2]. Although many questions exist regarding the
introduction of a pay for performance (P4P) system into
the ﬁeld of urology, this new powerful movement cannot be
ignored.
Unfortunately, the majority of currently established
quality measures are designed primarily for primary care
physicians and institutional providers such as hospitals. Ini-
tialperformancemeasuresthatcouldbeappliedtourological
patients have been released by CMS as part of its physician
voluntaryreportingprogress(PVRP)program[3].Examples
include the use of thromboembolic and antibiotic prophy-
laxis in surgical patients [3]. However, these P4P strategies
currently embody rudimentary structure and process (as
opposed to outcomes) metrics which set relatively low-
performance thresholds [3]. Further, current P4P quality2 Advances in Urology
assessment programs are generally structured using negative
reinforcement strategies which penalize providers with lower
reimbursement when performance standards are not met,
but which often keep maximum attainable reimbursement at
predeﬁnedparvalues[4].Examplesinclude“straightbonus”,
“at-risk ﬁnancial”, and “tiered copayment” models which
may be either “competitive” (bonus payments distributed
to providers based on performance stratiﬁcations) or “non-
competitive” (bonus payments distributed to all providers
who meet a particular performance standard) [4].
The net result is that initial trials at P4P set a “low
bar” for quality and cost eﬃciency and, therefore, are
likely to produce only nominal improvements in clinical
outcomes measures with limited global impact [3]. More-
over, rudimentary P4P metrics are unlikely to diﬀerentiate
individual providers in a meaningful way on the basis
of clinical outcomes. Conversely, P4P strategies that align
reimbursement allocation with “free market” type shifts in
cognitive and procedural care using evidence-based data and
positive reinforcement are more likely to produce large-scale
improvements in quality and cost eﬃciency with respect to
clinical urologic care.
2. BPH EVIDENCE-BASED REVIEW OF COMMON
PROCEDURAL TREATMENT OPTIONS
The management of benign prostatic hyperplasia (BPH) can
serve as an excellent example of how eﬀective P4P paradigms
might be structured and implemented in urologic practice
to generate meaningful improvements in clinical outcomes.
BPH is one of the most common medical conditions in the
aging male population in the US [5]. As pharmacologic and
procedural therapies for this disease evolve, myriad studies
evaluating clinical eﬃcacy and cost eﬀectiveness have been
published. This body of research provides a unique lens
through which the problem of implementing P4P principles
in urology can be viewed.
Transurethral resection of prostate (TURP) is generally
the gold standard treatment for BPH against which the
clinical eﬃcacy of emerging technologies is measured. In
2003, Hoﬀman et al. published a systematic review of ran-
domized controlled trials to determine the clinical eﬃcacy
of TURP [6]. The pooled mean percentage improvement for
urinary symptoms ranged from 63% to 77% with standard
transurethral resection, while improvement for peak urinary
ﬂow ranged from 96% to 127%. In a comprehensive review
of clinical outcomes and costs for BPH procedural therapy
which included an analysis of the AUA BPH guideline
dataset, researchers reported average TURP improvements
frombaseline AUA symptom score,maximum uroﬂowmetry
rate, and quality of life scores of 66%, 117%, and 73%,
respectively, 2 years after treatment [7].
Complications of TURP are well documented in the
literature. Rassweiler et al. recently updated the rates of
complications for TURP, including information on man-
agement and prevention based on technological evolution
[8]. In that study, technological improvements such as the
use of microprocessor-controlled units, the implementation
of video-assisted TURP, and comprehensive training helped
to reduce perioperative complications (recent versus early)
including transfusion rate (0.4% versus 7.1%), TUR syn-
drome (0.0% versus 1.1%), clot retention (2% versus 5%),
and urinary tract infection (1.7% versus 8.2%). However,
a comprehensive outcomes review by Rhee et al. showed
that TURP is associated with a substantial risk of complica-
tions including blood transfusion, TUR syndrome, urinary
incontinence, infection, impotence, ejaculatory dysfunction,
irritative voiding symptoms, stricture, hematuria, urinary
retention, and the need for retreatment which eﬀects both
treatment eﬃcacy and the cost of care [9].
Evidence-based studies that analyze total cost of care for
procedural BPH therapies are also available. One sophisti-
cated peer reviewed economic analysis estimated the total
payer cost over a 2 year period from the time of treatment,
including the cost of initial treatment, follow-up care,
adverse events, and procedural retreatment. According to
this study, the 24-month total procedural cost of TURP was
$4927 [7]. With regards to physician reimbursement, the
Medicare 2008 fee schedule ﬁgure is approximately $783.11
for the common hospital-based site of service (Table 1, 2008
Medicare Payment Schedule).
Laser vaporization of the prostate (PVP and HoLAP)
has gained popularity due to the ability of this procedure
to ablate large volumes of prostate tissue with decreased
riskofcomplications.Additionaladvantagesincludereduced
need for hospitalization, shorter catheterization times, and
excellent clinical eﬃcacy compared to standard procedu-
ral therapies and emerging minimally invasive treatments.
Rajbabu et al. studied the eﬃciency of photoselective
vaporization of the prostate (PVP) with the potassium
titanyl phosphate (KTP) laser in men with prostates of
>100 grams [10]. The mean maximum urinary ﬂow rate
(standard deviation) improved from 8.0 (3.1) to 18.2 (8.1),
18.5 (9.2), 17.9 (7.8), and 19.3 (9.8) mL/s at 3, 6, 12,
and 24 months, respectively. The IPSS and quality of life
(QoL) scores showed similar improvements. There were no
majorcomplications,andnopatientdevelopedtransurethral
resection syndrome or required a blood transfusion [10].
Tan et al. have also published on the clinical eﬃcacy of this
technique [11].
Other researchers have performed formal meta-analysis
of KTP laser vaporization demonstrating improvements in
symptom score, maximal ﬂow rate, and QoL scores of 76%,
221%,and83%at24months,respectively[7].Further,when
compared to ILC, TUNA, TUMT, and TURP, laser vaporiza-
tiondisplayedverylowadverseeventratesincludingtherisks
of incontinence, UTI, impotence, ejaculatory dysfunction,
irritative voiding, bladder neck stenosis/stricture, urinary
retention, hematuria, and reoperation [7].
These investigators estimated the 24-month total pro-
cedural cost, including expenditures for initial treatment,
follow-up care, adverse events, and procedural retreatment
to be $3589 [7]. The 2008 Medicare fee schedule reimburse-
ment for laser vaporization diﬀers signiﬁcantly based on
the site of service with approximate physician fee schedule
reimbursement of $648.11 and $2498.50 for procedures
performed in the hospital and oﬃce settings, respectively
(Table 1, 2008 Medicare payment schedule).M. Stovsky and I. Jaeger 3
Table 1: 2008 Medicare physician payment data for BPH procedural therapies (ﬁgures are derived using the CMS listing for the 2008 fee
schedule, the 2008 conversion factor, and the RBRVS formula).
CPT code/procedure Nonfacility Medicare payment schedule 2008 Facility Medicare payment schedule 2008
52601 (TURP complete) N/A $783.11
52647 (Indigo laser) $2457.86 $606.77
52648 (contact laser vaporization of prostate) $2498.50 $648.11
52649 (laser Enucleation of the Prostate) N/A $951.99
55821 (prostatectomy, suprapubic simple) N/A $829.45
53850 (microwave thermotherapy) $2901.75 $536.34
53852 (radiofrequency ablation) $2891.72 $582.43
Interstitial laser coagulation (ILC) of the prostate can
be performed in the hospital inpatient, hospital outpatient,
ambulatory surgery center, or oﬃce settings under local,
regional, or general anesthesia. In 1998, Williams reported
the introduction of a volume-based treatment formula with
12-month follow-up [12]. In this study, treatment outcomes
were evaluated at 3-, 6-, and 12-month intervals using the
AmericanUrologicalAssociation(AUA/IPSS)BPHsymptom
score, maximal urinary ﬂow, prostate size, and postvoid
residual urine volume. The AUA symptom score decreased
from 23.2 (range 17–28) prior to treatment to 9.4 (range 4–
14)at3months,6.6(range5–12)at6months,and7.2(range
4–11) at 12 months. The maximal ﬂow rate improved from
8.4 (range 5–10) milliliters per second before treatment to
14.1 (range 10–20) mL/s at 3 months, 14.8 (range 10–18)
mL/sat6months,and16.8(range12–25)mL/sat12months
aftertreatment.Inaddition,Williamsreportednosigniﬁcant
postprocedure complications [12]. Other investigators, in
a more recent comprehensive review and meta-analysis of
ILC published studies, demonstrated average improvements
from baseline of 62%, 89%, and 55% for AUA symptom
score, maximum uroﬂowmetry rate, and the quality of
life score, respectively, at 24 months posttreatment [7].
Unfortunately, ILC has demonstrated a relatively high risk of
reoperation with one study reporting 16% of men requiring
TURP within 2 years of initial treatment of 16% [13].
In comparison, another peer-reviewed report using for-
mal meta-analysis techniques demonstrated relatively high
adverse event rates and a weighted average probability of
retreatment of 10% along with a 24-month total procedural
cost (including cost of initial treatment, follow-up care,
adverse events, and procedural retreatment) of $4754 [7].
As with laser vaporization, the 2008 Medicare physician
reimbursement depends on the site of service in which the
procedure is performed. In that regard, the approximate
physician reimbursement for ILC is $606.77, and $2457.86
forthehospitalandoﬃcesettings,respectively(Table 1,2008
Medicare payment schedule).
Transurethral Radiofrequency needle ablation (TUNA)
of prostate is generally performed in the outpatient set-
ting under local or regional anesthesia. Bouza et al. per-
formed a systematic review and meta-analysis of TUNA
in symptomatic BPH [14]. Although evidence was lim-
ited by methodological issues, the analysis indicated that
while TUNA signiﬁcantly improved BPH parameters with
respect to baseline, these improvements did not match
those achieved with TURP. In addition, the clinical eﬃcacy
declinedinthelongtermwitharetreatmentratesigniﬁcantly
higher than that of TURP [14].
In a review and meta-analysis of minimally invasive BPH
procedural therapies, TUNA demonstrated improvements
frombaseline AUA symptom score,maximum uroﬂowmetry
rate, and quality of life scores of 52%, 35%, and 68%, respec-
tively,at6monthsaftertreatment[7].Theseratesdeclinedat
24monthsfollowupto44%improvementinsymptomscore
and 28% improvement in uroﬂowmetry rates. However,
the improvement of quality of life score appeared to be
maintained at 61% [7]. This report also demonstrated the
probabilities of adverse events for the procedure to be
signiﬁcant, including a 31% rate of dysuria/irritative voiding
symptoms, 20% risk of urinary retention, and 17% chance
of urinary tract infection. The weighted average reoperation
rate reported in this study was 23%, the highest of all
treatment modalities reviewed [7].
The 24-month total procedural cost including expendi-
tures for initial treatment, follow-up care, adverse events,
and procedural retreatment has been estimated at $6179 [7].
An analysis of 2008 Medicare physician reimbursement for
TUNA shows approximate values of $582.43 and 2891.72 for
the facility and nonfacility settings, respectively. In practice,
however, the procedure is generally performed in the oﬃce
site of service by most physicians (Table 1, 2008 Medicare
payment schedule).
Transurethral microwave therapy (TUMT) of the
prostate also aﬀords the advantage of being performed in
the oﬃce setting using minor sedation and local anesthesia.
In evaluating clinical measures of eﬃcacy, Hoﬀman et al.
performed a review of randomized controlled trials to
evaluate urinary symptom improvement, urinary function,
prostate volume, mortality, morbidity, and retreatment rates
[15]. In that evaluation, the pooled mean urinary symptom
scores decreased by 65%, while the pooled mean peak
urinary ﬂow rates increased by 70%. Compared to TURP,
TUMT was associated with decreased risk of retrograde
ejaculation, the formation of clinically signiﬁcant strictures
and hematuria, the need for blood transfusions, and the
development of transurethral resection syndrome. However,
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dysuria and urinary retention as well as the need for
retreatment related to deterioration in BPH symptoms [15].
An analysis of reported outcomes data from the com-
prehensive AUA BPH guidelines demonstrated 39%–46%
symptom score improvement at 24 months [7]. Maximal
uroﬂowmetry rate and quality of life score improvements
ranged from 28%–45% and 24%–52% at 24 months, respec-
tively [7]. The weighted average probability of an adverse
event varied based on the equipment used, with a 74% rate
of dysuria/irritative voiding for the Prostatron Version 2.5
versus 28% when using the Prostatron Version 2.0. The rates
of reoperation again varied depending on the system used,
ranging from 10% to 16% [7]. Other commonly reported
adverse events included incontinence (range 2–6%), UTI
(9%), impotence (range 1–3%), stricture (range 1–3%), and
retention (range 6–23%) [7].
In that study, the expected cost per patient at 24 months,
including expenditures for initial treatment, follow-up care,
adverse events, and procedural retreatment was $5461 when
using Prostatron 2.0, $5488 with Prostatron 2.5 and $5699
with the Targis system [7].
A review of 2008 Medicare fee schedule physician
reimbursement for TUMT indicates an approximate value
of $2901.75 in the oﬃce site of service and $536.34 for a
hospital-based procedure (Table 1, 2008 Medicare payment
schedule). However, virtually, all TUMT procedures are
currently performed in the oﬃce outpatient setting.
Laser enucleation of the prostate (HoLEP) is generally
performed in the hospital outpatient or inpatient setting and
provides a relatively minimally invasive means of removing
a broad range of obstructing prostate adenomas. Studies of
clinical eﬃcacy have documented profound improvements
in outcomes metrics including symptom score, quality of life
score, and uroﬂowmetry rates that compare favorably to the
gold standard TURP procedure [16, 17]. In addition, HoLEP
tends to produce relatively low-adverse event rates including
objective assessments for the risks of transfusion, impotence,
irritative voiding, retention, incontinence, stricture, and UTI
compared to other BPH ablation procedures [16–19]. How-
ever, HoLEP carries a relatively high risk of bladder mucosal
injury andasteeplearning curvetoachievetechnical compe-
tence relative to other transurethral therapies. While meta-
analytic cost data comparing HoLEP to other procedural
BPH therapies is not generally available, the approximate
2008 Medicare fee schedule physician reimbursement for
this procedure is $951.99 utilizing a hospital site of service
(Table 1, 2008 Medicare payment schedule).
3. STRUCTURING PAY FOR PERFORMANCE IN
UROLOGY: THE BPH EXAMPLE
Armed with a thorough understanding of clinical outcomes,
cost,andreimbursementdataforcommonlyperformedBPH
procedural options, it is now possible to examine oppor-
tunities for developing P4P programs in urology using this
disease entity as an example. To be sure, few would dispute
the conceptual value of transforming the current system
of medical service reimbursement with a more rationale,
evidence-based approach. The challenge in proposing a P4P
scheme for BPH procedural therapy is to understand the
method by which physician reimbursement for professional
servicesiscalculatedandtheroleofthissystemininﬂuencing
clinical outcomes. Then, a proposal can be developed which
outlines potential ways that physician payment allocation
might be restructured to drive aggregate physician decision
makingtowardtheselectionofproceduralservicesthatresult
in improved outcomes while also preserving free choice from
a market basket of therapeutic alternatives with heteroge-
neous clinical and economic performance characteristics.
The ﬁrst step in proposing an eﬀective pay for perfor-
mance initiative for BPH procedural therapy is to inter-
nalize the complexity of the calculation used to formulate
Medicare reimbursement for speciﬁc treatment options.
At its core, the resource-based relative value scale system
for physician payments (RBRVS) was developed from the
principle that the “relative value” of physician services is
comprised of 3 essential components: (1) the physician work
expended performing a medical service, (2) the practice
expense attributable to providing that service, and (3) the
component of malpractice expense that can be allocated
to the distinct procedural or cognitive care [20]. Total
Medicare health care expenditures are limited based on the
sustainable growth rate (SGR) method which is, in turn,
linked to changes in the gross domestic product (GDP)
[20]. Critical ﬂaws of the current system of determining
physician payments for medical services include problems
with the calculation of actual work input values for speciﬁc
services, the inconsistent allocation of practice expenses for
hospital, ambulatory surgery center and oﬃce-based care,
and the coupling of health expenditures with GDP which
may not reﬂect inﬂationary pressures speciﬁc to the practice
of medicine. However, most important to the discussion of
P4Pimplementationinurologyisthetotalabsenceofclinical
and economic outcomes measures or performance standards
in the RBRVS calculation.
A review of the previous analysis of outcomes, cost,
and physician payment data for BPH procedural treatment
in the context of the RBRVS methodology provides an
unambiguous view of the way that reimbursement strategies
can aﬀect clinical outcomes. From this review, two major
points are evident. First, physician reimbursement for BPH
procedural therapy demonstrates marked variation based
primarily on diﬀerences in key inputs to the RBRVS calcu-
lation which are impacted by the technologies employed and
the site of service utilized in performing these procedures.
Second, even allowing for adjustments based on procedural
overhead cost, there is clear misalignment between evidence-
based clinical outcomes measures and current Medicare fee
schedulephysicianreimbursementforcommonlyperformed
BPH procedures.
This misalignment creates an environment in which
choices between objective outcomes measures and physician
reimbursement are in competition during the process of
BPH procedural treatment selection. In this way, the cur-
rent reimbursement paradigm for BPH procedural therapy
actually works to select for less optimal clinical outcomes
as physicians are forced into an awkward position, where
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outcomes and reimbursement at the same time. To be sure,
other factors should also play a substantial role in determin-
ing the appropriate BPH procedural treatment for a given
patient.Propertreatmentselectionshouldreﬂectsoundjoint
decision making and consumer-centered care that reﬂects
both the physician’s use of evidence-based information and
the incorporation of patient speciﬁc factors including the
relative importance of adverse event rates, comorbidities,
location of service, objective clinical improvement, and
cost. However, by placing reimbursement and outcomes in
direct opposition, the current volume-based methodology
for allocating physician reimbursement for BPH therapies
creates a sizeable barrier to the development of a workable
pay for performance program.
Addressing the challenge of proposing a viable P4P
paradigm for BPH procedural treatment or any other
medical service requires several important steps. First,
policymakers must ﬁx the RBRVS/SGR methodology to
resolve recurring problems with the econometric formula
including, but not limited to, inaccuracies in the estimation
of the practice expense component for procedural reim-
bursement and the ﬂawed link between physician payment
calculations and variation in the GDP [20]. Second, the
RBRVS formula should be modiﬁed to embody clinical
outcomes performance metrics using, for example, addi-
tional factors that reﬂect the relative diﬀerence between
individual procedures and services based on measurable
evidence based data. Finally, key reimbursement deci-
sion makers should change the frame of reference from
a punitive system of individual physician performance
assessment to a “supply side” approach which utilizes
a realignment of physician payments with outcomes to
inﬂuence aggregate physician-patient joint decision mak-
ing.
The potential beneﬁts to structuring an eﬀective pay
for performance paradigm for BPH procedural therapy are
enumerable. Eﬀective treatment selection can have an enor-
mous impact on downstream outcomes indicators including
the degree of clinical improvement and the risk of adverse
events which, in turn, largely determine the real cost of care
[7]. Further, pay for performance methodologies that use
physician reimbursement as an incentive to value-based (as
opposed to volume-based) decision making are more likely
to result in sustainable quality improvement [20]. Properly
structured P4P programs can then form the foundation
upon which eﬀective reimbursement strategy is built.
Conversely, punitive P4P programs that use rudimentary
structure and process metrics are unlikely to produce lasting
quality or cost improvements as these methodologies do
little to promote competition based on the overall value
of medical services provided [20]. Moreover, these crude
measures create performance standard thresholds that are
relatively easy to achieve and that promote the tendency to
shape clinical decision making simply to satisfy a particular
quality metric [3]. The net result of P4P programs based on
individual physician performance assessment is a tendency
toward interval scale rankings that are unable to accurately
diﬀerentiate providers based on quality of care and which do
not address the misalignment of reimbursement and clinical
outcomes present in the current payment paradigm for BPH
procedures.
Hypothetically, physician reimbursement for BPH pro-
cedures can be structured in at least 3 basic ways. At
one extreme, physician payments can be allocated without
incorporating clinical outcomes measures in the calculation.
This case example results in the current system, where
the choice from among competing alternatives is based on
a number of interrelated factors. In this scenario, while
procedures with superior eﬃcacy will sometimes be chosen,
clinical outcomes in the aggregate will never be optimized
as competing incentives allow less eﬃcacious treatments
to be selected disproportionately. At the other extreme,
physician payments can be allocated equally among the
various treatment alternatives. This case would result in an
environment, where there is no direct economic incentive to
choose any one BPH treatment. In this scenario, treatment
decision making may result in the selection of procedures
with healthier outcomes characteristics but the lack of
economic incentives would continue to result in a subset
of providers utilizing less eﬃcacious alternatives for other
reasons including diﬀerences in the learning curve to master
particular techniques and the capacity of some technologies
to be more amenable to volume-based practice.
In the end, value-based P4P is the only practicable way to
appropriately structure BPH procedural treatment selection
to improve clinical outcomes by aligning the interests of
physicians, patients, and payers with rational reimbursement
policy. In this case, physician payments would be weighted
and allocated based on a validated analysis of evidence-
based outcomes data. BPH procedures that exhibit better
outcomes performance characteristics would be allocated
greater physician reimbursement and competition between
reimbursement and outcomes would be curbed. Moreover,
value-based P4P that utilizes clinical outcomes as the core
performance measure, as opposed to punitive structure and
process metrics, would move away from individual physician
performance assessment with its inherent limitations to a
system that maintains free choice from among the available
treatment alternatives while at the same time providing
market-based positive reinforcement to globally inﬂuence
aggregate physician decision making toward procedures with
superior outcomes characteristics (in much the same way,
for instance, as the federal reserve shapes ﬁnancial decisions
through manipulations of key interest rates and the money
supply). In this way, the frame of reference and focus
appropriately shifts from the individual provider to the
therapies provided and allows physicians and patients to
make rational, evidence-based treatment decisions.
Certainly, the rate limiting step in the development of
value-based P4P for BPH procedural treatment or any other
medical condition is the availability of clinically meaningful
outcomes criteria which can be populated with uniform
evidence-based data [3]. However, previous research has
indeed shown that high quality meta-analysis of AUA
guideline and other peer-reviewed data can be performed
and meshed with Medicare cost ﬁgures to compare BPH
procedures in an unbiased fashion [7]. Further, value-based
P4P canintegratemoresophisticatedmetricsincluding“total6 Advances in Urology
cost of care” which by incorporating factors such as the costs
of initial therapy, follow-up care, management of adverse
events, and retreatment can act as a valuable measure of
clinical eﬃcacy [7].
In conclusion, doctors and other providers should be
rightly cautious about current P4P initiatives that use
rudimentary metrics and punitive reimbursement policy
and which fail to diﬀerentiate participants or improve
aggregate clinical outcomes. However, urologists, patients,
and payers should embrace the concept of value-based pay
forperformanceasareimbursementsystemwiththepotential
to align the interests of these distinct constituencies and
to improve global clinical outcomes while preserving free
choice of clinically eﬃcacious treatments.
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